# Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

> **NCT02032784** · PHASE4 · TERMINATED · sponsor: **AdventHealth** · enrollment: 33 (actual)

## Conditions studied

- Adenoma

## Interventions

- **DRUG:** octreotide
- **OTHER:** No Octreotide

## Key facts

- **NCT ID:** NCT02032784
- **Lead sponsor:** AdventHealth
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2018-06-28
- **Final completion:** 2020-07-06
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Difficult to enroll subjects
- **Last updated:** 2020-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02032784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02032784, "Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02032784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*